Shanghai OPM Biosciences Co., Ltd. (SHA:688293)

Market Cap	5.80B +19.7%
Revenue (ttm)	354.91M +19.4%
Net Income	41.70M +98.1%
EPS	0.37 +105.6%
Shares Out	130.04M
PE Ratio	120.54
Forward PE	45.98
Dividend	0.42 (0.94%)
Ex-Dividend Date	n/a

Volume	810,630
Average Volume	1,229,157
Open	42.72
Previous Close	42.97
Day's Range	42.20 - 44.90
52-Week Range	31.85 - 67.80
Beta	0.72
RSI	40.78
Earnings Date	Apr 23, 2026

About Shanghai OPM Biosciences

Shanghai OPM Biosciences Co., Ltd. provides cell culture media and CDMO services in China and internationally. The company offers cell culture media and feed supplements, such as OPM's CHO-Platform, OPM-293 Platform, and VegaCHO media and feeds, as well as customized cell culture media development services. It also provides end-to-end biologics CDMO services, such as antibody discovery, stable cell line development, cell banking, upstream process development, downstream process development, formulation development, and quality control and produ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 64
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688293

Financial Performance

In 2025, Shanghai OPM Biosciences's revenue was 354.91 million, an increase of 19.40% compared to the previous year's 297.24 million. Earnings were 41.70 million, an increase of 98.07%.